At week 68, six participants (66.7%) had no change, two participants (22.2%) increased and one participant (11.1%) decreased the number of antihypertensive medications from baseline
Material that is described in commerce as "retatrutide" is therefore either (a) supplied to participants enrolled in an Eli Lilly clinical trial, (b) supplied as a chemical reference standard for laboratory research use only, or (c) sold illicitly, which has been the focus of FDA enforcement [5][6][13][14]
Current interventional therapies for MS, known as DMTs, include dimethyl fumarate (468), fingolimod (469), natalizumab (470), ocrelizumab (471) and others
GLP-1 RA (glucagon-like peptide-1 receptor agonists) are associated with decreased cardiovascular disease, mainly driven by reduced stroke risk, and have gained interest as therapeutic agents for stroke recovery in experimental stroke models